Adamantyl cannabinoids: A novel class of cannabinergic ligands

Dai Lu, Zhaoxing Meng, Ganesh A. Thakur, Pusheng Fan, John Steed, Cindy L. Tartal, Dow P. Hurst, Patricia H. Reggio, Jeffrey R. Deschamps, Damon A. Parrish, Clifford George, Torbjörn U.C. Järbe, Richard J. Lamb, Alexandras Makriyannis

Producción científica: Articlerevisión exhaustiva

63 Citas (Scopus)

Resumen

Structure-activity relationship studies have established that the aliphatic side chain plays a pivotal role in determining the cannabinergic potency of tricyclic classical cannabinoids. We have now synthesized a series of analogues in which a variety of adamantyl substituents were introduced at the C3 position of Δ8-THC. Our lead compound, (-)-3-(1-adamantyl)- Δ8-tetrahydrocannabinol (1a, AM411), was found to have robust affinity and selectivity for the CB1 receptor as well as high in vivo potency. The X-ray crystal structure of 1a was determined. Exploration of the side chain conformational space using molecular modeling approaches has allowed us to develop cannabinoid side chain pharmacophore models for the CB1 and CB2 receptors. Our results suggest that although a bulky group at the C3 position of classical cannabinoids could be tolerated by both CB1 and CB2 binding sites, the relative orientation of that group with respect to the tricyclic component can lead to receptor subtype selectivity.

Idioma originalEnglish (US)
Páginas (desde-hasta)4576-4585
Número de páginas10
PublicaciónJournal of Medicinal Chemistry
Volumen48
N.º14
DOI
EstadoPublished - jul 14 2005

ASJC Scopus subject areas

  • Drug Discovery
  • Molecular Medicine

Huella

Profundice en los temas de investigación de 'Adamantyl cannabinoids: A novel class of cannabinergic ligands'. En conjunto forman una huella única.

Citar esto